VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

35 hedge funds and large institutions have $25.4M invested in Viracta Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

less funds holding

Funds holding: →

less first-time investments, than exits

New positions opened: | Existing positions closed:

less capital invested

Capital invested by funds: $ → $
Holders
35
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$119K
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$529K
2
+$189K
3
+$104K
4
TI
Telemetry Investments
New York
+$71.3K
5
GPP
Great Point Partners
Connecticut
+$51.5K

Top Sellers

1
-$1.1M
2
-$1.03M
3
-$158K
4
DCM
DAFNA Capital Management
California
-$36.9K
5
Renaissance Technologies
Renaissance Technologies
New York
-$31.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$25K
27
$22K
28
$20K
29
$17K
30
$16K
31
$9K
32
–
33
–
34
–
1
2